169 related articles for article (PubMed ID: 23302815)
1. Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse--Tennessee, 2012.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2013 Jan; 62(1):1-4. PubMed ID: 23302815
[TBL] [Abstract][Full Text] [Related]
2. Opana ER abuse and thrombotic thrombocytopenic purpura (TTP)-like illness: a rising risk factor in illicit drug users.
Kapila A; Chhabra L; Chaubey VK; Summers J
BMJ Case Rep; 2014 Mar; 2014():. PubMed ID: 24591390
[TBL] [Abstract][Full Text] [Related]
3. Opana-ER used the wrong way: intravenous abuse leading to microangiopathic hemolysis and a TTP-like syndrome.
Amjad AI; Parikh RA
Blood; 2013 Nov; 122(20):3403. PubMed ID: 24369032
[No Abstract] [Full Text] [Related]
4. Bilateral exudative retinal detachments due to thrombotic microangiopathy associated with intravenous abuse of Opana ER.
Aseem F; Zamora BG; Kauffman L; Miller PJ; John VJ
Am J Ophthalmol Case Rep; 2018 Sep; 11():72-74. PubMed ID: 29998206
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange.
Miller PJ; Farland AM; Knovich MA; Batt KM; Owen J
Am J Hematol; 2014 Jul; 89(7):695-7. PubMed ID: 24668845
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic microangiopathy and acute kidney injury associated with intravenous abuse of an oral extended-release formulation of oxymorphone hydrochloride: kidney biopsy findings and report of 3 cases.
Ambruzs JM; Serrell PB; Rahim N; Larsen CP
Am J Kidney Dis; 2014 Jun; 63(6):1022-6. PubMed ID: 24529995
[TBL] [Abstract][Full Text] [Related]
7. Resurgence of intravenous Opana as a cause of secondary thrombotic thrombocytopenic purpura.
Rane M; Aggarwal A; Banas E; Sharma A
Am J Emerg Med; 2014 Aug; 32(8):951.e3-4. PubMed ID: 24630802
[No Abstract] [Full Text] [Related]
8. THROMBOTIC MICROANGIOPATHY ASSOCIATED WITH OPANA ER INTRAVENOUS ABUSE A Case Report.
Jabr FI; Yu L
J Med Liban; 2016; 64(1):40-2. PubMed ID: 27169165
[TBL] [Abstract][Full Text] [Related]
9. Acute kidney injury is common with intravenous abuse of extended-release oral oxymorphone and delayed renal recovery rates are associated with increased KDIGO staging.
Bonnecaze AK; Wilson MW; Dharod A; Fletcher A; Miller PJ
Nephrology (Carlton); 2018 Oct; 23(10):921-926. PubMed ID: 28802086
[TBL] [Abstract][Full Text] [Related]
10. A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER.
Hunt R; Yalamanoglu A; Tumlin J; Schiller T; Baek JH; Wu A; Fogo AB; Yang H; Wong E; Miller P; Buehler PW; Kimchi-Sarfaty C
Blood; 2017 Feb; 129(7):896-905. PubMed ID: 27864296
[TBL] [Abstract][Full Text] [Related]
11. Thrombotic Microangiopathy Secondary to Intravenous Abuse of Opana® ER.
Thakur K; Agrawal V; Kass A; Dimarino LM; Dorion RP; Vadakara J
Case Rep Hematol; 2017; 2017():1623907. PubMed ID: 28607779
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Intensive Care Unit Admission and Sequelae in Patients Intravenously Abusing Extended-Release Oral Oxymorphone.
Wilson MW; Bonnecaze AK; Dharod A; Miller PJ
South Med J; 2017 Mar; 110(3):217-222. PubMed ID: 28257549
[TBL] [Abstract][Full Text] [Related]
13. Opioid associated intravenous and cutaneous microvascular drug abuse (skin-popping) masquerading as Degos disease (malignant atrophic papulosis) with multiorgan involvement.
Magro CM; Toledo-Garcia A; Pala O; Momtahen S; Shapiro L
Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437280
[TBL] [Abstract][Full Text] [Related]
14. Opana(®) ER induced thrombotic thrombocytopenic purpura.
Kotbi N; Han B; Cheng D; Odom AE
Int Med Case Rep J; 2015; 8():97-8. PubMed ID: 25995651
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
Hale ME; Ahdieh H; Ma T; Rauck R;
J Pain; 2007 Feb; 8(2):175-84. PubMed ID: 17145204
[TBL] [Abstract][Full Text] [Related]
16. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
Steinhubl SR; Tan WA; Foody JM; Topol EJ
JAMA; 1999 Mar; 281(9):806-10. PubMed ID: 10071001
[TBL] [Abstract][Full Text] [Related]
17. Opana-induced thrombotic microangiopathy masquerading as thrombotic thrombocytopenic purpura.
Ban BH; Verma A; Tudor M; Sethi J
Oxf Med Case Reports; 2017 Jun; 2017(6):omx026. PubMed ID: 28580158
[TBL] [Abstract][Full Text] [Related]
18. Opana ER (Oxymorphone)-Induced Thrombotic Microangiopathy: An Atypical Presentation in a Patient With Hepatitis C.
Mehmood H; Khan M; Marwat A; Joshi M; Malhotra V
J Investig Med High Impact Case Rep; 2018; 6():2324709618756423. PubMed ID: 29435466
[TBL] [Abstract][Full Text] [Related]
19. Thrombotic microangiopathy associated with intravenous injection of extended-release oxycodone.
Robson KJ; Clucas D; Filshie R; Nandurkar H
BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28716778
[TBL] [Abstract][Full Text] [Related]
20. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs.
Cicero TJ; Ellis MS; Kasper ZA
Pain; 2016 Jun; 157(6):1232-1238. PubMed ID: 27186712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
